Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Am J Clin Pathol. 2012 Aug;138(2):223-9. doi: 10.1309/AJCPPVX91HQMNYZZ.
The use of human papillomavirus DNA testing plus Papanicolaou (Pap) testing (cotesting) for cervical cancer screening in women 30 years and older has been recommended since 2006. However, few studies have detailed the adoption of such cotesting in clinical practice. We examined the trends in monthly percentage of Pap tests ordered as cotests in our laboratory over a 2.5-year period and used joinpoint regression to identify periods in which there was a change in the average monthly proportion of cotests. Cotesting of patients 30 years and older increased from 15.9% in January 2008 to 39.4% in June 2010. In patients aged 18 to 29 years, cotesting initially increased, but showed a downward trend in the last 14 months of the study, ending at 7.7% in June 2010. Our study highlights increased adoption of age-appropriate cotesting as well as the persistence of age-inappropriate cotesting.
自 2006 年以来，一直推荐将人乳头瘤病毒 DNA 检测与巴氏涂片（Pap）检测（联合检测）联合用于 30 岁及以上女性的宫颈癌筛查。然而，很少有研究详细描述这种联合检测在临床实践中的应用。我们研究了在过去 2.5 年中我们实验室每月订购巴氏涂片联合检测的百分比趋势，并使用连接点回归来确定平均每月联合检测比例发生变化的时期。30 岁及以上患者的联合检测从 2008 年 1 月的 15.9%增加到 2010 年 6 月的 39.4%。在 18 至 29 岁的患者中，联合检测最初增加，但在研究的最后 14 个月呈下降趋势，2010 年 6 月降至 7.7%。我们的研究强调了适龄联合检测的采用增加，以及不适当年龄的联合检测的持续存在。
